镇咳、祛痰药物研究进展

发布时间：2018-02-25 05:18

本文关键词： 镇咳药祛痰药研究进展　出处：《中国药房》2015年25期 　论文类型：期刊论文

【摘要】：目的:为开发新型镇咳、祛痰药物提供参考。方法:以"镇咳药""祛痰药""研究进展""Antitussive""Expectorant"等为关键词,组合查询2003-2014年中国知网、万方、Pub Med、Scopus等数据库中的相关文献,将镇咳药物按受体的不同进行分类分析,而祛痰药物则按作用机制的不同进行归纳。结果:共查询到相关文献80余条,有效文献29条。其中具有良好开发前景的新型镇咳药物主要有速激肽受体拮抗药、P2X受体拮抗药、选择性大麻素受体激动药、瞬时受体电位香草酸亚型1受体拮抗药、p38丝裂原活化蛋白激酶抑制剂等;祛痰药物的研究仍局限于黏液溶解药、恶心性祛痰药、黏液润滑药3种。结论:目前,新型的镇咳药物已逐渐向疗效更广、更具受体选择性的方向发展,而祛痰药物则未见有较大的突破。
[Abstract]:Objective: to provide a reference for the development of new antitussive and expectorant drugs. Methods: taking "antitussive drugs," "expectorant drugs", "research progress", "Antitussive" and "Expectorant" as the keywords, the relevant documents in the database of "Pub MedScopus" from 2003 to 2014 in China were searched. The antitussive drugs were classified according to the different receptors, while the expectorant drugs were concluded according to the different mechanism of action. There are 29 effective documents. Among them, the new antitussive drugs with good development prospects are mainly the tachykinin receptor antagonists, P2X receptor antagonists, selective cannabinoid receptor antagonists, and the selective cannabinoid receptor antagonists. Transient receptor potential vanillic acid subtype 1 receptor antagonists, such as p38 mitogen-activated protein kinase inhibitors, and expectorant drugs are still limited to three kinds of mucolytic drugs, nausea expectorants and mucus lubricating drugs. The new antitussive agents have gradually developed towards wider efficacy and more receptor selectivity, while expectorant drugs have not made a great breakthrough.
【作者单位】：中山大学中山医学院;中山大学中山医学院病理生理学教研室;
【基金】：2014年大学生创新创业训练计划项目(No.20140558075)
【分类号】：R974

【参考文献】